Incidental diagnosis of moderate congenital factor XI deficiency in a child during preoperative screening : a case report
This case report describes the incidental diagnosis of moderate congenital factor XI deficiency in a 3-year-old Moroccan boy during preoperative screening for circumcision, highlighting the importance of investigating isolated prolonged aPTT even in the absence of a significant bleeding history to ensure appropriate management before invasive procedures.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human body relies on a complex, silent network of proteins to keep blood flowing smoothly and to stop bleeding when a vessel is damaged. This process, known as coagulation, involves a chain reaction where one protein activates the next, much like a line of falling dominoes. When this chain is broken at a specific point, the body cannot form a stable clot, leading to a bleeding disorder. While some of these conditions are well-known and cause spontaneous bleeding, others are far more subtle. One such condition involves a protein called factor XI, which plays a role in the early stages of the clotting chain. Unlike its more famous relatives, a shortage of factor XI does not always lead to dramatic bleeding. In fact, many people with this deficiency live without knowing they have it until a doctor notices a strange result on a routine blood test. This uncertainty creates a challenge for medical teams: how do you decide if a patient is safe for surgery when their blood test looks abnormal, but their body seems fine?
This question lies at the heart of a recent case report from a hospital in Rabat, Morocco, which details the story of a three-year-old boy. The child arrived at the hospital for a routine preoperative check before a planned circumcision. During the standard screening, a laboratory technician noticed that one specific test, which measures how long it takes for blood to clot, was taking longer than usual. This test, known as the activated partial thromboplastin time, was significantly delayed, while all other standard blood counts and clotting tests appeared normal. The medical team faced a puzzle: the boy had no history of severe bleeding, no family history of blood disorders, and no signs of spontaneous hemorrhage. Yet, the blood test suggested something was missing from his clotting chain.
To solve this puzzle, the doctors performed a series of careful investigations. They first mixed the boy's blood with normal blood to see if the delay in clotting would disappear. When the delay vanished, it confirmed that the boy was missing a specific clotting protein rather than having a substance in his blood that was blocking the process. The team then measured the levels of the individual proteins involved. They found that two common clotting factors were present in normal amounts, but the level of factor XI was lower than expected. Specifically, the boy's factor XI activity was measured at 41.2 percent, a level that classifies the condition as a moderate deficiency. This confirmed a diagnosis of congenital factor XI deficiency, a rare inherited condition also known as hemophilia C.
The discovery presented a critical decision point for the medical team. In many bleeding disorders, a low level of a clotting factor automatically triggers a plan to replace the missing protein before surgery. However, the relationship between the amount of factor XI and the risk of bleeding is not straightforward. A person with very low levels might never bleed, while another with moderate levels might bleed heavily. The doctors looked closely at the boy's history and found that he had only experienced minor bruising after small bumps, with no episodes of nosebleeds, gum bleeding, or joint bleeding. Based on this specific clinical picture, combined with the laboratory results, the team decided that the boy did not need special blood products or factor replacement therapy for his upcoming procedure.
The circumcision was performed without any complications, and the boy recovered with no postoperative bleeding. This outcome supports the idea that for factor XI deficiency, the best way to predict bleeding risk is not just by looking at a number on a lab report, but by understanding the patient's personal history. The case illustrates that a low factor XI level does not always mean a patient needs aggressive treatment. Instead, it highlights the need for doctors and laboratory specialists to work together, weighing the test results against the individual's life and medical history to make safe, personalized decisions. The parents expressed relief that the team identified the issue beforehand and managed it without unnecessary interventions, allowing the routine procedure to proceed safely. This story serves as a reminder that in medicine, the most important data point is often the patient themselves, not just the numbers on a page.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.